Also known as: Guardant Health
Guardant Health is a precision oncology company focused on blood-based cancer testing and data-driven cancer care. Founded in 2012 and headquartered in Redwood City, it is listed on Nasdaq under GH.
Genomic medicine market is projected to reach USD 123 billion by 2035; AI in genomics USD 6.5 billion; viral vector manufacturing USD 15.83 billion. Gene therapy trials drive growth.
The GE HealthCare-Mayo MI-BET collaboration advances biomarker-guided prostate cancer therapy. The precision oncology market, valued at $122.6B in 2025, is projected to reach $317.2B by 2034, fueled by genomics and targeted treatments.
Guardant Health said its chief medical officer will resign effective May 8, while Delfi Diagnostics appointed Charles Newton to its board and Singular Genomics named John Stark CEO.
The AI-driven precision medicine market is projected to grow from $0.7 billion in 2025 to $9.7 billion by 2035 at a 26.8% CAGR. North America dominates with 62-67% market share, while machine learning accounts for 39% of the market. The market is moderately consolidated with the top five players controlling over 64% share.
The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.
